In consideration of the dual roles of GLP-1RAs in hypoglycemic effects and preventing CVD among T2DM patients, we reviewed the cardiovascular effects and molecular mechanisms of GLP-1RAs in CVOTs, animal models and cultured cells, and discuss how these findings transform pharmacotherapies for T2DM, and even expand the indication of this important category of anti-diabetic drugs to CVD patients without diabetes
New Developments in GLP-1 Agonists The field of GLP-1 agonists is rapidly advancing, with new treatments being tested
The promising combination of nanocarriers and intranasal delivery needs to elucidate better clinical, pharmacokinetics, and safety profiles
These fractional units are genuinely difficult to measure on standard syringes
Your medication, delivered If approved, your lipotropic injections ship in 35 days with discreet packaging, so you can start your journey
, , , - ,